Drug
At2221
At2221: highest development phase Phase 3, developed by Amicus Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amicus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AT2221 NCT04138277 | Phase 3 | Pompe Disease (Late-onset) |
Latest
No recent events.
Follow At2221 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.